SITC Announces 2023 Class of Fellows to the Academy of Immuno-Oncology

The Society for Immunotherapy of Cancer (SITC) announces the 2023 Class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2023 class will be inducted at a private event during SITC’s 38^th Annual Meeting & Pre-Conference Programs, taking place November 1–5, 2023 in San Diego, CA.

Read More >>

Latest Press Releases

11/3/23 - FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer

10/31/23 - FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma

10/27/23 - SITC Announces Biotech Initiative and Committee

10/25/23 - SITC Announces Late-Breaking Abstracts and Press Briefing Presented at 38^th Annual Meeting

10/20/23 - SITC Publishes Clinical Practice Guideline Immunotherapy for Melanoma, V3.0

10/18/23 - FDA Approves Neoadjuvant/ Adjuvant Pembrolizumab for Resectable Non-Small Cell Lung Cancer

10/17/23 - FDA Grants Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma

10/6/23 - SITC and the International Bladder Cancer Group Publish Recommendations for Clinical Trial Design in Bladder Cancer

9/6/23–Society for Immunotherapy of Cancer Announces 2023 Annual Award Recipients

8/30/23–SITC Announces 2023 Class of Fellows to the Academy of Immuno-Oncology

8/16/23–SITC's Forward Fund Announces 2023 Fellowship Awardees

8/15/23−FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma

8/14/23−FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple Myeloma

8/1/23−FDA Approves Dostarlimab-gxly with Chemotherapy for Endometrial Cancer

6/15/23−SITC Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Gynecologic Cancer

6/12/23−SITC Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Gastrointestinal Cancer

5/22/23−FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Diffuse Large B-cell Lymphoma

5/10/23−SITC Announces Keynote Speakers Dr. Susan Kaech and Dr. Robert D. Schreiber at its 38th Annual Meeting

4/6/23−FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

3/23/23−FDA Grants Accelerated Approval to Retifanlimab-dlwr for Metastatic Merkel Cell Carcinoma

1/27/23 –FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

11/11/22 –FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for Metastatic Non-Small Cell Lung Cancer

11/10/22 –FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer

11/3/22 –SITC to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting

11/2/22 –SITC 2022 Late-Breaking Abstracts Announced

10/26/22 –FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

10/25/22 – FDA Approves Tremelimumab in Combination with Durvalumab for unresectable hepatocellular carcinoma

10/7/22 – The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology

10/5/22 – Black and African American Professionals Discuss Barriers in Biomedical Field

9/8/22 – Oncology News Burst from FDA: durvalumab

8/30/22 – SITC Announces Annual Award Recipients

8/11/22 – SITC Forward Fund Announces 2022 Fellowships and Tech Award Recipients

7/14/22 – SITC Announces 2022 Class of Fellows to the Academy of Immuno-Oncology

7/12/22 – SITC to Convene Oncology Leaders to Address Crisis in Clinical Research at Virtual Summit

5/18/22 – SITC Announces Keynote Speaker Dr. Padmanee Sharma and Keynote Panel Honoring the Work of Dr. Zelig Esshar at its 37^th Annual Meeting

5/10/22 – SITC’s Steven A. Rosenberg Scholars Award: $150,000 in Funding for an Emerging Leader in Immuno-Oncology

4/26/22 – Cancer Researchers to Rock Buddy Guy’s Legends for One Night Only

3/9/22 – Oncology News Burst from FDA: Nivolumab

1/13/22 – SITC to Offer Program for Emerging Leaders in Cancer Immunotherapy Focused on Accelerating Professional Development and Innovative Collaborations

SITC Communications
communications@sitcancer.org
+1 414-271-2456